Patient reported outcomes in adults with severe eosinophilic asthma on benralizumab.

Trial Identifier: D3250R00041
Sponsor: AstraZeneca
NCTID:: NCT03833141
Start Date: November 2018
Primary Completion Date: May 2024
Study Completion Date: May 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Alberta Calgary, Alberta, Canada, T3B 0M3
Canada, Alberta Calgary, Alberta, Canada, T2N 1N4
Canada, Alberta Edmonton, Alberta, Canada, T5H 4B9
Canada, Alberta Edmonton, Alberta, Canada, T5J 3S9
Canada, Alberta Red Deer, Alberta, Canada, T4N 1L1
Canada, Alberta Sherwood Park, Alberta, Canada, T8H 0N2
Canada, British Columbia Vancouver, British Columbia, Canada, V6Z 1Y6
Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 4E1
Canada, New Brunswick Bathurst, New Brunswick, Canada, E2A 1A9
Canada, Ontario Ajax, Ontario, Canada, L1S 2J5
Canada, Ontario Burlington, Ontario, Canada, L7N 3V2
Canada, Ontario Kitchener, Ontario, Canada, N2M 5E2
Canada, Ontario North Bay, Ontario, Canada, P1B 4Y3
Canada, Ontario Toronto, Ontario, Canada, M4V 1R2
Canada, Ontario Toronto, Ontario, Canada, M5G 1E2
Canada, Ontaro Barrie, Ontaro, Canada, L4N 7L3
Canada, Quebec St-Charles-Borromee, Quebec, Canada, J6E 2B4
Canada, Quebec Trois-Rivieres, Quebec, Canada, G8T 7A1
Canada, Saskatchewan Regina, Saskatchewan, Canada, S4P 1Y8
Canada, Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 0W8